Ideaya Biosciences, Inc. · NASDAQ:IDYA
Ideaya Biosciences — JPM Healthcare Conference January 2021
25 slides from Ideaya Biosciences's conference presentation, Jan 11, 2021
Slide 1: IDEAYA Biosciences: Improving Lives Through Transformative Precision Medicines
IDEAYA Biosciences Improving Lives Through Transformative Precision Medicines JPM Healthcare Conference January 2021 Exhibit 99.1 NASDAQ: IDYA
Slide 2: Forward-Looking Statements
Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other factors t
Slide 3: IDEAYA Biosciences Highlights and Target 2021 Synthetic Lethality Catalysts
Target 2021 Synthetic Lethality Catalysts IDE397 IND-filed, Best-in-Class Profile Present +40 MTAP-deletion PDX Study data Phase 1 FPI and Clinical Pharmacodynamic Data Enable Clinical Combo w/ GSK Type I PRMT Select PARG Development Candidate Select Pol Theta Development Candidate IDEAYA SL Investo
Slide 4: Synthetic Lethality: The Next Frontier in Precision Medicine Oncology
Synthetic lethality occurs when the simultaneous perturbation of two genes results in cell death Synthetic lethal interactions with tumor-specific mutations (biomarker) may be exploited to develop anticancer therapies Large-scale screening for synthetic lethal targets has progressed through advances
Slide 5: IDEAYA's Precision Medicine Oncology Pipeline
IDEAYA’s Precision Medicine Oncology Pipeline 5 Building the Industry Leading Synthetic Lethality Focused Biotechnology Company Precision Medicine Pipeline Pursuant to GSK Collaboration, Option and License Agreement: MAT2A and WRN: 50/50 US Profits + ex-US Royalties; Polq: Global Royalties Pursuant
Slide 6: IDEAYA Team and Scientific Advisory Board
IDEAYA Team and Scientific Advisory Board 6 Proven Team & Scientific Thought Leaders in Precision Medicine Oncology IDEAYA Executives & R&D Leadership IDEAYA Scientific Advisory Board Yujiro Hata, M.B.A. President, Chief Executive Officer, Director Paul Stone, J.D. SVP, Chief Financial Officer Micha
Slide 7: IDEAYA and GSK Strategic Partnership
IDEAYA and GSK Strategic Partnership 7 Landmark Partnership in Synthetic Lethality Validates IDEAYA Synthetic Lethality platform Creates 3 strategic combination opportunities Advancing small molecules & protein degraders Transformative Strategic Partnership $100M cash upfront $20M equity investment
Slide 8: Synthetic Lethality Target Discovery and Drug Discovery Platform
8 SL Target & Biomarker Discovery and Validation Bioinformatics, including AI Algorithms Dual CRISPR, CRISPR, siRNA Genetically Engineered Models Drug Discovery and Pharmacological Validation Structure Based Drug Design Small Molecule Chemistry Protein Degrader Capabilities 1st-in-class SL targets i
Slide 9: Synthetic Lethality Target Discovery & Validation Platform
Partnership Datasets Cancer Dependency Map – Broad Institute Foundation Insights™ – Foundation Medicine 9 IDEAYA Synthetic Lethality Platform Synthetic Lethality Target and Biomarker Discovery and Validation DECIPHER™ Dual CRISPR SL Library in DNA Damage Repair (2) PAGEO™ Paralogous Gene Evaluation
Slide 10: DECIPHER Dual CRISPR Synthetic Lethality Library
10 IDEAYA Synthetic Lethality Platform Synthetic Lethality Target and Biomarker Discovery and Validation DECIPHER™ Dual CRISPR SL Library in DNA Damage Repair (1) Evaluation of DNA Damage Targets synthetic lethal with tumor suppressor or oncogenes DECIPHER™ Dual CRISPR Proprietary Synthetic Lethalit
Slide 11: IDE397 (MAT2A/MTAP) Lead SL Program
IDE397 (MAT2A/MTAP) Lead SL Program IND Filed Potential First-in-Class Monotherapy and First-in-Class / Best-in-Class Combination Therapies (Type I PRMT, Taxanes) Targeting PARG and Pol Theta Development Candidates in 2021 PARG monotherapy efficacy in multiple tumor types; Pol Theta + PARPi combinat
Slide 12: MTAP Deletion Prevalence and MTAP-MAT2A Synthetic Lethality Biology
MTAP Deletion Prevalence MTAP-MAT2A Synthetic Lethality Biology MAT2A Inhibition is Synthetic Lethal with MTAP Deletion 12 MTAP Deletion Prevalence ~15% of all Solid Tumors Data from The Cancer Genome Atlas in cBioPortal MAT2A MAT2A inhibitor MAT2A Methionine MAT2A is key enzyme that produces SAM in
Slide 13: IDE397: MAT2A Development Candidate
IDE397: MAT2A Development Candidate 13 Clinical Evaluation of IDE397 – Differentiated Profile and Selective for MTAP-/- Cell Lines IDE397 demonstrates in vivo efficacy and PD modulation at 5 to 30mg/kg AG270 published preclinical dose typically 200mg/kg 1 IDE397 has not caused preclinical liver inju
Slide 14: Monotherapy Tumor Regressions Across Multiple Solid Tumor Types
14 Monotherapy Tumor Regressions & Significant TGI Across Multiple Solid Tumor Types 1 Esophageal PDX Model Gastric PDX Model Bladder PDX Model IDE397 PDX Study of >40 MTAP-/- Models in Multiple Indications IDE397 evaluation in Patient Derived Xenograft (PDX) models with homozygous MTAP deletions in
Slide 15: IDE397 Monotherapy Demonstrates Tumor Regressions in NSCLC
Robust dose dependent PD modulation observed in NSCLC CDX Model 15 NSCLC MTAP-/- PDX Models NSCLC Endogenous MTAP-/- CDX Model Tumor stasis to regressions in endogenous MTAP-/- CDX and PDX NSCLC Models 1 IDE397 Monotherapy Demonstrates Tumor Regressions in NSCLC (1) IDEAYA PDX Study data targeted to
Slide 16: IDE397 + Type I PRMT (GSK3368715) Combination Rationale
IDE397 + Type I PRMT (GSK3368715) Combination Rationale 16 Mohammad et al., GSK, Cancer Cell July 2019 Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss Dual ADMA plus SDMA reduction enhances preclinical anti-tumor activity in MTAP-delet
Slide 17: IDE397 Monotherapy in MTAP-Deletion: Phase 1 Clinical Trial Execution
IDE397 Monotherapy in MTAP-Deletion: Phase 1 Clinical Trial Execution 17 Patient Selection, Trial Design and Pharmacodynamic (PD) Biomarkers MTAP Gene Deletion and Protein Level Confirmation MTAP Deletion detected by commercial and institutional NGS screening panels MTAP IHC assay developed and vali
Slide 18: ~75,000 Patients per Year in US, EU5, and Japan
18 ~75,000 Patients per Year in US, EU5, and Japan H&E Tumor Cells 1 MTAP Protein 2 H score = 100 H score = 2 MTAP WT MTAP Deleted Patient Selection: Based on NGS and/or IHC to identify patients with MTAP-deletion Patient Population: ~75,000 patients per year in US, EU5 and Japan H&E stain identifie
Slide 19: PARG Synthetic Lethality Program
PARG Synthetic Lethality Program 19 Targeting Development Candidate in 2021 PARG Biology PARG Novel target in Clinically Validated Pathway Poly(ADP-ribose) glycohydrolase (PARG) regulates DNA repair by hydrolyzing PAR chains in final step of DDR cycle Multiple potent cellularly active compounds demo
Slide 20: IDB-PARGi Demonstrates Tumor Regressions in Defined Biomarker Setting
20 Monotherapy Regressions in Multiple Indications with enhanced activity vs. PARP Inhibitor Tumor Type 3 CDX Model Tumor Type 2 CDX Model Tumor Type 1 CDX Model IDB-PARGi Demonstrates Tumor Regressions in Defined Biomarker Setting Evaluation of IDB-PARGi in Cell-line Derived Xenograft (CDX) Models
Slide 21: Monotherapy Tumor Regressions Observed in Multiple PDX Models
21 Monotherapy Tumor Regressions observed in Multiple PDX Models Breast Cancer PDX Model Breast Cancer PDX Model Breast Cancer PDX Model PARG Breast Cancer PDX Study in Defined Biomarker Setting Evaluation of IDB-PARG in Patient Derived Xenograft (PDX) Models in Breast Cancer Tumor Regressions (> 10
Slide 22: Pol Theta Synthetic Lethality Program
Pol Theta ATPase inhibitor In Vivo Activity Pol Theta Synthetic Lethality with BRCA/HRD Pol Theta Pol Theta Synthetic Lethality Program 22 Targeting Development Candidate in 2021 IDEAYA Data DNA polymerase theta (Pol Theta) promotes DNA repair by Microhomology-Mediated End-Joining (MMEJ) an error-pr
Slide 23: Werner Helicase Synthetic Lethality Program
Werner Inhibitor Cellular PD and Viability Werner Helicase Synthetic Lethality Program 23 Candidate Biomarker: High-MSI (15% GI Cancers and 16% CRC) 1 PD-marker: dose dependent increase of DNA damage marker gH2AX Cell viability: MSI-high specific cell viability effect; no effect in MSS cell lines In
Slide 24: MUM Indication: Focus on Clinical Combos
MUM Indication: Focus on Clinical Combos IDE196 + MEK (binimetinib) & IDE196 + cMET (crizotinib) IDE196 + MEK & IDE196 + cMET preclinical synergy demonstrated2 Study goal is to enhance IDE196 mono clinical activity in MUM IDE196 mono BID (30 pts), ~73% Disease Control Rate & ~13% ORR1 Pfizer Clinica
Slide 25: Building the Premier Synthetic Lethality Focused Oncology Biotech in 2021 and Beyond
Building The Premier Synthetic Lethality Focused Precision Medicine Oncology Biotech in 2021 and Beyond 25 Large addressable patient populations in major solid tumor types Best-in-class small molecule and protein degrader development candidates Compelling patient biomarker hypotheses SL platform to
IDEAYA Biosciences — JPM Healthcare Conference January 2021 on 6ix